ArticleNature immunology2017
Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8
Article in Nature immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- The challenge and promise of studying human antigen-specific T cells.Nature reviews. Immunology · 2026Review
- Heterogeneity and dynamics of DENV-specific CD8 + T cells in dengue infection.Nature communications · 2026Article
- TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how.Journal for immunotherapy of cancer · 2026Review
- T Cell Responses During Dengue Infection.Current topics in microbiology and immunology · 2026Review
- Integrated Methodology from Synthesis toNano letters · 2025Article
- Occlusion of TCR binding to HLA-A*11:01 by a non-pathogenic human alloantibody.Cellular and molecular life sciences : CMLS · 2025Article
- The Evolving T Cell Receptor Recognition Code: The Rules Are More Like Guidelines.Immunological reviews · 2025Review
- Article
- Identification and affinity enhancement of T-cell receptor targeting a KRASCommunications biology · 2024Article
- The molecular mechanisms of CD8Frontiers in immunology · 2024Review
- Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.Nature communications · 2023Article
- Integrated systems immunology approach identifies impaired effector T cell memory responses as a feature of progression to severe dengue fever.Journal of biomedical science · 2023Article
- The superantigens SpeC and TSST-1 specifically activate TRBV12-3/12-4Communications biology · 2023Article
- Preparation and pre-clinical evaluation of flagellin-adjuvanted NOM vaccine candidate formulated with Spike protein against SARS-CoV-2 in mouse model.Microbial pathogenesis · 2022Article
- Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information.Nucleic acids research · 2022Article
- Current Understanding of the Role of T Cells in Chikungunya, Dengue and Zika Infections.Viruses · 2022Review
- Pathogenesis and virulence of flavivirus infections.Virulence · 2021Review
- Immune cell phenotypes associated with disease severity and long-term neutralizing antibody titers after natural dengue virus infection.Cell reports. Medicine · 2021Article
- TCR Recognition of Peptide-MHC-I: Rule Makers and Breakers.International journal of molecular sciences · 2020Review
- SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors.Immunity · 2020Article
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Funding
Abstract
Adaptive immune responses protect against infection with dengue virus (DENV), yet cross-reactivity with distinct serotypes can precipitate life-threatening clinical disease. We found that clonotypes expressing the T cell antigen receptor (TCR) β-chain variable region 11 (TRBV11-2) were 'preferentially' activated and mobilized within immunodominant human-leukocyte-antigen-(HLA)-A*11:01-restricted CD8
Indexed as
Identifiers
28945243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.